Aytu Revenue Rises to $14.842 Million as Tender Offer Remains Pending
Revenue was $13.888 million in the year-earlier quarter. Aytu also had $25.5 million in cash and cash equivalents.

Aytu BioPharma, Inc. posted $14.842 million in net revenue for the quarter ended Sept. 30, 2026, up from $13.888 million a year earlier, as Rosemont’s $2.70 cash offer remained pending.
The agreement announced Nov. 16 calls for Rosemont Pharmaceuticals’ wholly owned subsidiary to offer $2.70 in cash for each outstanding Aytu common share. The tender offer had not commenced as of Nov. 16 and is subject to conditions, including tenders covering a majority of Aytu’s outstanding shares. The agreement has no financing condition.
Aytu had $25.5 million in cash and cash equivalents. The company will not hold an earnings call because of the pending merger.
“We see a strong strategic fit between our portfolio and Rosemont’s experience developing and commercializing specialty medicines,” Aytu CEO Josh Disbrow said.